People without insurance in St. Louis tend to carry a set of assumptions about depression care that were learned the hard way: a bill that came as a shock, a clinic that turned them away, a friend's story about a treatment that cost a fortune. Some of those assumptions are accurate. Others keep people from options that are actually open to them.
Here are six common ones, checked against what is known and against our publisher's commissioned survey of 443 Midwest adults. The survey numbers are final and validated; most are whole-sample, and a few describe the 39 respondents who were uninsured.
"Without insurance, there is nowhere to go for depression."
Not true. Both St. Louis city and the county have federally qualified health centers whose fees follow income, and many pair behavioral health with primary care. Around the region, publicly supported mental health centers and behavioral health clinics exist to see people whatever their ability to pay. Search by ZIP code with the federal locator, findahealthcenter.hrsa.gov.
These are not luxury clinics, and there may be a wait. But they are real doors, and a clinician there can diagnose depression, adjust medications, and refer you onward.
"I already checked. I don't qualify for Medicaid."
Worth checking again. Medicaid expansion in Missouri made many lower-income working-age adults eligible for MO HealthNet. Plenty of people who were denied before expansion never applied again. If your income has dropped, your household has changed, or you last checked several years ago, the answer may be different now.
If you do not qualify for Medicaid, a marketplace plan with income-based subsidies may cost less than you expect, and a qualifying life change can open enrollment outside the usual window.
Coverage is not a side issue in depression treatment. Eighty-five percent of the adults we surveyed rated it one of their two biggest provider priorities. For the uninsured respondents, the share was 72 percent.
"The ketamine clinic I saw advertised is the same as Spravato."
No. Spravato is esketamine, a nasal spray with two FDA-approved adult indications: depression that has resisted other treatment, and major depression that brings acute suicidal thinking or behavior. Every dose happens in a certified setting, and observation lasts at least two hours afterward.
Many cash-pay clinics in the St. Louis area and online offer ketamine by IV infusion or as tablets or lozenges for use at home. Those uses of ketamine for depression are off-label. At-home use happens without anyone monitoring you in person, and the FDA has warned about the risks. That does not automatically make every such provider a bad choice, but they are not interchangeable with esketamine. A plain Spravato explainer lays out the approved version.
The confusion is understandable. Most people do not know the name Spravato at all. In our survey, the "never heard of it" share came to nearly three quarters, 73 percent. Recognizing the name without understanding it accounted for a fifth more, and genuine familiarity was down at 6 percent. Uninsured respondents knew even less: 85 percent had never heard of Spravato. When one version of a treatment advertises and the other mostly does not, the advertised one becomes the default in people's minds.
"Paying cash is always faster and simpler."
Sometimes faster. Rarely simpler over the long run. A self-pay clinic may book you sooner. But treatment-resistant depression care is rarely a single visit. Esketamine, for example, typically starts with two sessions a week for about a month, then continues at a lower frequency. Any course of care has to be affordable over months, not just on day one.
Our respondents split on this. Faced with a choice between covered care with more hoops and self-pay care with a quicker, simpler start, 23 percent would pay themselves, while 51 percent would put up with the hoops for coverage. The remaining 26 percent could not decide. Both preferences are reasonable. Just make the choice knowing the full cost, in writing.
"I need to know the exact treatment I want before I see anyone."
You do not. Respondents' likely search phrases were things like "how to cope with my anxiety," "help with mental health," and "depressed." Drug names were essentially absent. That is normal. Your job is to describe what is happening and what you have tried. The clinician's job is to connect that to options.
Most people in our survey planned to lean on a professional. Primary care doctors were the top first stop at 56 percent, psychiatrists and other mental health providers came next at 23 percent, and only 12 percent would start by researching alone.
"Asking about cost up front is rude or makes them treat you worse."
It is standard practice. Clinics that serve uninsured patients answer cost questions all day. Asking early helps them steer you toward programs you can afford, including manufacturer assistance programs for specific medications, sliding-scale therapy, or help applying for coverage. Useful questions:
- What will today's visit cost, and what would follow-up visits cost?
- If you recommend a treatment, can I get a written estimate for the full course?
- Do you have a financial counselor or navigator who helps with coverage applications?
- Is there an assistance program for this medication?
What stays true
Being uninsured does make depression care harder. It narrows choices, adds paperwork, and forces tradeoffs no one should have to make while depressed. None of that is imaginary. But the door is rarely fully closed, and the first step, finding one clinician who will see you, is usually more reachable than it looks from the outside.
Deciding if esketamine or anything else suits you takes a medical judgment, drawn from your history and health, by a clinician who has examined you.
If you are at the point of thinking about suicide, please reach out before anything else. Dial or text 988, where the Suicide and Crisis Lifeline is free, open every hour, indifferent to insurance, and ready for veterans who press 1.
Methodology
Data comes from a survey we placed on the Pollfish consumer panel, where 443 adults aged 18 to 64 responded from Kansas, Iowa, Missouri, Nebraska, Oklahoma, Illinois, Indiana, Ohio, Wisconsin, and Minnesota before answers stopped on June 23, 2026. Uninsured figures aside, results describe the whole sample, with none by location. Every figure has been through Pollfish's final validation. Our publisher commissioned the study and covered its expense.